MedPath

Neutral and Positive Attention Bias Modification Training for Young Adults With Depressive Symptoms

Not Applicable
Completed
Conditions
Depressive Disorder
Interventions
Behavioral: Neutral ABMT
Behavioral: Positive ABMT
Registration Number
NCT03971942
Lead Sponsor
Hunan Normal University
Brief Summary

This study intends to explore the therapeutic effects of the development of negative attention bias modifaction and positive attention bias on depressive symptoms and redundancy through two different attention training methods: (1) neutral attention training (when neutral and sad stimuli are presented simultaneously, attention is always directed towards neutral stimuli to correct negative attention bias) and (2) positive attention training (when neutral and positive stimuli are presented simultaneously, attention is always directed towards positive stimuli to develop positive attention bias).

Detailed Description

Attention Bias Modification Training was a modified dot-probe task. In the neutral attention bias, 90% of the targets in the training group appear in the neutral word position and 10% of the targets appear in the negative word position, while 50% of the targets in the placebo group appear in the neutral word position and 50% of the targets appear in the negative word position. In the positive attention bias, 90% of the targets in the training group appear in the positive word position and 10% of the targets appear in the neutral word position, while 90% of the targets in the placebo group appear in the neutral word position and 10% of the targets appear in the positive word position. The investigators assess attention bias scores, depressive symptoms, trait anxiety, rumination and self-report attention control ability at 1-week, 2-week, 4-week, 7-week, 3-month, 4-month, 5-month, 6-month and 12-month follow-ups after training.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
68
Inclusion Criteria
  • A score of 14 or higher on the Beck Depression Inventory-Ⅱ
Exclusion Criteria
  1. a current episode of MDD, bipolar disorder, schizophrenia or organic mental disorder;
  2. any concurrent psychotherapy;
  3. any concurrent psychotropic medication.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Neutral ABMTNeutral ABMT8-session-ABMT during a two-week period and 4-session-booster-ABMT during a two-week period
Positive ABMTPositive ABMT8-session-ABMT during a two-week period and 4-session-booster-ABMT during a two-week period
Primary Outcome Measures
NameTimeMethod
Changes of attentional bias scorepre-training, post-training(2 weeks after pre-training), follow-ups(1-week,2-week,4-week,7-week,3-month( booster pre-training), 4-month (booster post-training), 5-month,6-month,12-month after post-training)

Attentional bias score tested by a typical dot-probe task

Changes of depressive symptomspre-training, post-training(2 weeks after pre-training), follow-ups(1-week,2-week,4-week,7-week,3-month( booster pre-training), 4-month (booster post-training), 5-month,6-month,12-month after post-training)

Depression symptoms tested by clinicians using the Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children (K-SADS)

Secondary Outcome Measures
NameTimeMethod
Changes of self-reported depressive symptomspre-training, post-training(2 weeks after pre-training), follow-ups(1-week,2-week,4-week,7-week,3-month( booster pre-training), 4-month (booster post-training), 5-month,6-month,12-month after post-training)

Self-reported depressive symptoms assessed by Beck depression scale-second version (BDI-II)

Changes of self-reported ruminationpre-training, post-training(2 weeks after pre-training), follow-ups(1-week,2-week,4-week,7-week,3-month( booster pre-training), 4-month (booster post-training), 5-month,6-month,12-month after post-training)

Self-reported rumination assessed by Rumination Response Scale(RRS).

Trial Locations

Locations (1)

Department of Psychology, Hunan Normal University

🇨🇳

Changsha, Hunan, China

© Copyright 2025. All Rights Reserved by MedPath